New ADHD Therapies Make Splash, Meet Payer Skepticism
Editor’s note: A previous version of this article incorrectly stated that Ehave, Inc. is the manufacturer of EndeavorRx. The digital therapeutic device is made by Akili Interactive. This version has been corrected.
In recent months, some innovative treatments have emerged for attention deficit hyperactivity disorder (ADHD), which affects millions of children and is one of the most common neurodevelopmental disorders in childhood. But because those therapies are so new — and in one case, very unconventional — payers appear reticent to change their coverage tactics to accommodate them.
© 2023 MMIT